CV-6209 is a potent antagonist ofplatelet activating factor (PAF). CV-6209 inhibits the PAF-induced aggregation of rabbit and human platelets, withIC₅₀s of 75 nM and 170 nM, respectively. CV-6209 can inhibit PAF-induced hypotension in rats^[1].

platelet activating factor (PAF)^[1]

CV-6209 inhibits [³H]serotonin release from rabbit platelets stimulated with PAF (30 nM)^[1].
CV-6209 has little action on platelet aggregation induced by arachidonic acid, ADP, or collagen^[1].
CV-6209 (0.2-2 μM; pretreated for 30 min) inhibits PAF-induced MC degranulation in both LAD2 and hLMCs^[1].

CV-6209 (i.v.) inhibits PAF (0.3 μg/kg; i.v.)-induced hypotension in rats (ED₅₀=0.009 mg/kg) with no effect on the hypotension induced by arachidonic acid, histamine, bradykinin and isoproterenol^[1].
CV-6209 (66 μg; i.v.) reduces asparaginase-induced hypersensitivity compared with nonpretreated, sensitized mice^[3].

642.31

C₃₄H₆₀ClN₃O₆

100488-87-7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.